- November 20, 2020
- 11:00 AM - 12:00 PM ET
This webinar, and the guidance it accompanies, is intended to help applicants submitting an abbreviated new drug application (ANDA) seeking approval of a generic drug to identify:
- a reference listed drug (RLD), i.e., a previously approved drug product on which an applicant relies in seeking approval of a generic drug;
- a reference standard, i.e., the previously approved drug selected by FDA that an applicant must use in conducting any in vivo bioequivalence testing required to support approval of its ANDA; and
- the basis of submission for the ANDA.
James Hanratty, JD
Division of Policy Development (DPD) | Office of Generic Drug Policy (OGDP) | Office of Generic Drugs (OGD) | Center for Drug Evaluation and Research (CDER)